QC Ware and IonQ Mapped Four Orbitals of a Cytochrome P450nor Active Site Onto Eight Qubits of IonQ Forte on 1 September 2026
Quentir Medicine Monitor
Evidence-based insights for quantum medicine.
How tightly a candidate binds its target is one important factor in whether a drug works, and metal centers are among the difficult cases to calculate: an iron atom sitting in the middle of an enzyme. On 1 September 2026 QC Ware and IonQ said they had measured a four-orbital slice of one such site on a quantum computer and landed close to the classical answer. QC Ware's Promethium platform did the classical preparation, IonQ's Forte trapped-ion processor took the quantum measurement through Amazon Braket, and the target was the heme active site of cytochrome P450nor. The workflow calculated an electrostatic interaction energy within 0.5 kcal/mol of classical benchmarks, roughly four percent, inside the one kcal/mol threshold conventionally called chemical accuracy.
The IonQ half of a workflow already run on IBM hardware
This is a follow-up. On 7 August 2026 this Monitor read the same QC Ware Promethium workflow running a nitric oxide reductase calculation on IBM's 156-qubit Heron processor. The platform, the enzyme family and the hybrid division of labor are unchanged; the processor underneath is what is new, which makes hardware portability the company's actual claim. Portability is not comparability: the August disclosure carried no numerical result that today's figure could be set against. Today's release adds four disclosures the August account did not carry: the 115-atom active-site model, its more than 1,000 molecular orbitals, the reduction to a four-orbital active space mapped onto eight qubits, and the 0.5 kcal/mol comparison itself.
What the quantum machine actually did
The quantum step ran on eight qubits of a 36-qubit machine, measuring a four-orbital slice carved out of a model containing more than a thousand molecular orbitals. Promethium built the model, identified the strongly correlated region, reduced it automatically to that active space, and computed the final interaction energies classically after Forte measured the qubits in a single basis. Everything before and after the quantum slice happened on classical hardware.
Which enzyme, and why the framing needs care
P450nor sits in the cytochrome P450 superfamily whose monooxygenase members carry out most human drug metabolism, and the release says exactly that. P450nor itself is something else: a fungal CYP55 nitric oxide reductase, characterized in Fusarium oxysporum among other fungi, reducing nitric oxide to nitrous oxide and taking its electrons straight from reduced nicotinamide adenine dinucleotide, NADH. The release names no organism and no accession. It is a well-characterized computational test case, which is a good reason to choose it for a hardware demonstration and a poor reason to describe the run as modeling human drug metabolism.
What the result can and cannot establish
The comparison target was a classical benchmark, so the classical answer existed first, and the companies report agreement for this known case. The announcement names no preprint, reports no shot count, gives no uncertainty on the 0.5 kcal/mol figure and does not identify which classical method produced the benchmark.
Inside the 156-Qubit Enzyme Calculation
QC Ware reports a molecular calculation on quantum hardware
QC Ware says it calculated the electrostatic interaction energy of nitric oxide reductase by combining GPU-accelerated molecular modeling, classical chemistry methods, and quantum measurements on IBM's 156-qubit Heron processor. The enzyme is chemically demanding because its active region contains metal. The public announcement makes the electrostatic interaction energy calculation concrete, but it does not disclose the molecular partition, circuit design, measurement count, error mitigation, reference value, or final numerical error. The release therefore supports a precise statement: QC Ware reports that a medically relevant class of molecular calculation reached named quantum hardware. It does not yet show that the quantum step improved the result.
The architecture has a clear division of labor
The hybrid chemistry workflow combines Promethium, GPU-accelerated molecular modeling, classical chemistry methods, and quantum measurements. The release does not disclose how work was partitioned among them. IBM's published description of Heron and System Two provides useful architectural context: its quantum processors operate with classical runtime servers and methods that divide larger calculations. The QC Ware release is the source for the later 156-qubit hardware claim. It also says the demonstration is not currently an integrated Promethium product capability. That sentence prevents a hardware claim from being mistaken for a production service.
The missing benchmark defines the next milestone
The announcement reports no quantum advantage and offers no comparison against a strong classical workflow for the same chemical task. Qubit count cannot supply that missing result. A buyer would need comparative accuracy, resources, runtime, repeatability, and a decision consequence for chemists. The public record therefore places the work at TRL 3: a vendor-reported hardware proof of concept for one molecular property. Its product boundary is commercially informative because it separates an experimental module from the platform available today. The next persuasive record would show what the quantum measurements add at a fixed cost or error, and whether that contribution changes a research decision.